Jpmorgan Chase & CO Reneo Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

$1.14 Trillion
Q2 2024

A detailed history of Jpmorgan Chase & CO transactions in Reneo Pharmaceuticals, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 7,922 shares of RPHM stock, worth $13,308. This represents 0.0% of its overall portfolio holdings.

Number of Shares

7,922

Previous 15,044 47.34%

Holding current value

$13,308

Previous $24,000 54.17%

% of portfolio

0.0%

Previous 0.0%

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 12, 2024	SELL	$1.51 - $1.9 $10,754 - $13,531	-7,122 Reduced 47.34%	7,922 $11,000
Q1 2024 May 10, 2024	SELL	$1.59 - $1.74 $1,799 - $1,969	-1,132 Reduced 7.0%	15,044 $24,000
Q4 2023 Feb 12, 2024	BUY	$1.34 - $8.43 $10,213 - $64,253	7,622 Added 89.1%	16,176 $25,000
Q3 2023 Nov 14, 2023	BUY	$5.44 - $8.13 $4,569 - $6,829	840 Added 10.89%	8,554 $65,000
Q2 2023 Aug 11, 2023	SELL	$5.44 - $10.5 $65,617 - $126,651	-12,062 Reduced 60.99%	7,714 $50,000
Q1 2023 May 11, 2023	BUY	$2.44 - $6.42 $756 - $1,990	310 Added 1.59%	19,776 $118,000
Q4 2022 Feb 13, 2023	SELL	$1.8 - $3.52 $12,403 - $24,256	-6,891 Reduced 26.14%	19,466 $45,000
Q3 2022 Nov 14, 2022	BUY	$2.35 - $4.85 $61,938 - $127,831	26,357 New	26,357 $88,000
Q2 2022 Aug 11, 2022	SELL	$1.96 - $3.04 $7,990 - $12,394	-4,077 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$2.94 - $9.07 $4,806 - $14,829	1,635 Added 66.95%	4,077 $12,000
Q4 2021 Feb 10, 2022	SELL	$6.07 - $9.68 $4,121 - $6,572	-679 Reduced 21.76%	2,442 $21,000
Q3 2021 Nov 12, 2021	BUY	$6.28 - $11.07 $19,599 - $34,549	3,121 New	3,121 $23,000

Others Institutions Holding RPHM

# of Institutions

Shares Held

29.3M

Call Options Held

51.7K

Put Options Held

View Full List

About Reneo Pharmaceuticals, Inc.

Ticker RPHM
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 24,479,600
Market Cap $41.1M
Description
Reneo Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the development of therapies for patients with rare genetic mitochondrial diseases. It develops REN001, a selective peroxisome proliferator-activated receptor delta agonist, which is in Phase IIb clinical trial in patients with primary mitochondrial myopathies, as w...

More about RPHM

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Account

Jpmorgan Chase & CO Reneo Pharmaceuticals, Inc. Transaction History